EDITORIAL
agreement between direct and indirect comparisons.
The transitivity and consistency conditions should be evaluated in all network meta-analysis, however, transitivity should be specially evaluated in indirect comparisons (6) .
There are some conditions to determine transitivity (13):
1. The common comparator must be similarly defined when it appears in only these kind of interventions could be compared but it would not be possible to make a comparison of A vs. C, which could be clinically important. In these occasions, the meta-analysis of indirect or network comparisons, would be useful. Whenever it is possible to find estimates of the effect of both direct comparisons and indirect comparisons, the information gathered could increase the precision and power of the effect estimate (8, 13) . Indirect comparisons require to establish concepts such as: transitivity and consistency that I will explain later (6) .
The geometry of the network
The graphic representation of the network will play a fundamental role in the transparency of the results and in the critical reading of it. This allows us to understand in one way or another, the strength of the evidence, the number of articles from which the information presented comes from (treatment nodes), the comparisons that have direct comparisons and those that present indirect or mixed comparisons and the number of patients with different comparisons, in such a way that confidence in the results is increased (8, 13, 14) .
When there is no evidence of union between two pairs of nodes, it means that no clinical experiments were identified for those specific treatments. There are different geometric shapes, depending on the clinical conditions that were studied. For example, if all the experiments are compared with placebo, the geometry will be of a star, on the other hand, if all the interventions are compared with the others, then it will be in the form of a polygon (14) (Figure-1) .
Concepts of validity of network meta-analysis: transitivity and consistency
For indirect or mixed comparisons, the studies must be comparable in terms of their design, the population, the duration of the treatment, the final outcome, as well as the variables that could modify the effect, in such a way that there is clinical homogeneity (13) . On the other hand, validity depends on a series of concepts and assumptions such as: transitivity and consistency or coherence (16) (17) (18) . The first one refers to supposing that if intervention B is better than A and intervention A is better than C, then B is better than C. The second one refers to the level of Consistency, on the other hand, assumes that direct and indirect evidence are estimates of the same parameter. That is, if the additional arm had been included in the experiments A vs B and B vs C, the estimate of the effect should have been similar. There should be no discrepancies among the effect of treatments between direct and indirect comparisons (indirect CA = direct CA) (14) (15) (16) (17) (18) .
Consistency can be evaluated and verified through statistical tests using different statistical tests such as: Bucher method or inconsistency factors (5, 14, 18) .
Network meta-analysis not only shows a numerical result; it can also show a qualitative component that allows to show gaps in research for the generation of new ideas. It might also evaluates the presence of biases, for example, reporting and publication biases, as well as suggesting subgroups analysis (19) .
This novel statistical technique could estimate a ranking or classification of treatments according to the probability of being the best or most effective intervention. This is determined by a concept called SUCRA (Surface Under the Cumulative Ranking Curve) (20) . This type of organization offers the clinician a better way of interpreting the results, to be applied to patients. However, before focusing on this aspect, a solid structure of the network and an appropriate systematic review should be considered to be able to trust the findings (4, 8) .
Writing the Network Meta-analysis
The actual recommendation is based on an actualization of the conventional PRISMA for systematic reviews that involve network meta--analyses, and so it has been named PRISMA--NMA. This checklist-model consists of 32 items, and this tool will allow an adequate report of this new statistical method, given some fundamental points (Table-1) (21-23).
TEcHNIQUE LIMITATIONS
As systematic reviews and meta-analysis are not a panacea, and should be conducted under strict and specific methodology conditions, indirect/mixed-treatment comparisons and network meta-analysis have also some potential risks. For example, both transitivity and consistency conditions, must be met, however, very frequently, publications using this novel technique, forget to assess and state them. Additionally, it should be said that the methods are still being developed, and so they are still of low statistic value, but they have a very promising future (9, 16, 17, 24) .
On the other side, the related methods could under or overestimate the effects of treatments, compared to the evidence that comes from direct comparisons (25) (26) (27) . Further advances in different statistical techniques are still required, in order to increase the available knowledge and so enhance its generalization and applicability on decision making (6).
cONcLUSIONS Systematic reviews and network meta--analysis, constitute a tool that can contribute to clinicians and investigators making decisions regarding patients' treatment.
This new methodology involves conducting an excellent, exhaustive, and rigorous systematic 
Objectives
Provide an explicit statement of questions being addressed, with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).
Methods
Protocol and registration Indicate whether a review protocol exists and if and where it can be accessed (e.g., Web address); and, if available, provide registration information, including registration number.
Eligibility criteria
Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. Clearly describe eligible treatments included in the treatment network, and note whether any have been clustered or merged into the same node (with justification).
Information sources Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
Search
Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study selection State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
Data collection process Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items
List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Geometry of the network
Describe methods used to explore the geometry of the treatment network under study and potential biases related to it. This should include how the evidence base has been graphically summarized for presentation, and what characteristics were compiled and used to describe the evidence base to readers.
Risk of bias within individual studies
Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
Summary measures
State the principal summary measures (e.g., risk ratio, difference in means). Also describe the use of additional summary measures assessed, such as treatment rankings and surface under the cumulative ranking curve (SUCRA) values, as well as modified approaches used to present summary findings from meta-analyses.
Planned methods of analysis
Describe the methods of handling data and combining results of studies for each network meta-analysis. This should include, but not be limited to: Handling of multi-arm trials; Selection of variance structure; Selection of prior distributions in Bayesian analyses; and Assessment of model fit.
Assessment of Inconsistency
Describe the statistical methods used to evaluate the agreement of direct and indirect evidence in the treatment network(s) studied. Describe efforts taken to address its presence when found
Risk of bias across studies Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
Additional analyses
Describe methods of additional analyses if done, indicating which were pre-specified. This may include, but not be limited to, the following: Sensitivity or subgroup analyses; Meta-regression analyses; Alternative formulations of the treatment network; and Use of alternative prior distributions for Bayesian analyses (if applicable).
Results

Study selection
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
Presentation of network structure Provide a network graph of the included studies to enable visualization of the geometry of the treatment network.
Summary of network geometry
Provide a brief overview of characteristics of the treatment network. This may include commentary on the abundance of trials and randomized patients for the different interventions and pairwise comparisons in the network, gaps of evidence in the treatment network, and potential biases reflected by the network structure.
Study characteristics
For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
Risk of bias within studies Present data on risk of bias of each study and, if available, any outcome level assessment.
Results of individual studies
For all outcomes considered (benefits or harms), present, for each study: 1) simple summary data for each intervention group, and 2) effect estimates and confidence intervals. Modified approaches may be needed to deal with information from larger networks.
Synthesis of results
Present results of each meta-analysis done, including confidence/credible intervals. In larger networks, authors may focus on comparisons versus a particular comparator (e.g. placebo or standard care), with full findings presented in an appendix. League tables and forest plots may be considered to summarize pairwise comparisons. If additional summary measures were explored (such as treatment rankings), these should also be presented.
Exploration for inconsistency
Describe results from investigations of inconsistency. This may include such information as measures of model fit to compare consistency and inconsistency models, P values from statistical tests, or summary of inconsistency estimates from different parts of the treatment network.
Risk of bias across studies Present results of any assessment of risk of bias across studies for the evidence base being studied.
review, that will serve as a source of information and ideas. We suggest further training in these techniques for readers, editors, reviewers, and investigators, in order to improve the quality of publications in biomedical journals.
Results of additional analyses
Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, metaregression analyses, alternative network geometries studied, alternative choice of prior distributions for Bayesian analyses, and so forth).
Discussion
Summary of evidence Summarize the main findings, including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy-makers).
Limitations
Discuss limitations at study and outcome level (e.g., risk of bias), and at review level (e.g., incomplete retrieval of identified research, reporting bias). Comment on the validity of the assumptions, such as transitivity and consistency. Comment on any concerns regarding network geometry (e.g., avoidance of certain comparisons).
Conclusions
Provide a general interpretation of the results in the context of other evidence, and implications for future research.
Funding Funding
Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. This should also include information regarding whether funding has been received from manufacturers of treatments in the network and/or whether some of the authors are content experts with professional conflicts of interest that could affect use of treatments in the network.
